



RPG LIFE SCIENCES LIMITED
Registered Office: RPG House,
463, Dr. Annie Besant Road,
Worli, Mumbai 400030, India.
Tel: +91-22-269757100
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN: L24232MH2007PLC169354

May 25, 2026

To

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we enclosed herewith the Investor's Presentation which will be made during RPG Annual Investor Conference 2026 scheduled to be held on May 26, 2026.

Kindly take the same on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

RAJESH
RAMESH
SHIRAMBEKAR
Digitally signed by
RAJESH RAMESH
SHIRAMBEKAR
Date: 2026.05.25
20:42:07 +05'30'

Rajesh Shirambekar
Head- Legal & Company Secretary

Encl: As above



hello happiness

RPG

Annual Investor Conference 2026

RPG Life Sciences

May 26, 2026



Disclaimer


This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

International Formulations (IF)

Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category



Leader in Immunosuppressants



9 Therapies represented by High Equity Brands



50+ Markets Presence



3 Manufacturing Facilities




1300+ Employees

RPG Life Sciences: Product Portfolio

Strong 'Textbook' brands ; ↑ Chronic and Specialty therapies

Key Therapies
Nephrology
Rheumatology
Oncology
Pain Management
Gastroenterology
Neuropsychiatry
Cardio- Diabeto
Urology

DF Key Products				
Legacy Portfolio		New Portfolio		
<p>Immunosuppressants</p> <p>Azoran Azathioprine</p> <p>Mofetyl Mycophenolate Mofetil</p> <p>Arpimune ME Cyclosporine</p> <p>Imunotac Tacrolimus</p>	<p>Textbook Brands</p> <p>Azoran Azathioprine</p> <p>Aldactone Spironolactone</p> <p>Lomotil Diphenoxylate HCl</p> <p>Naprosyn Naproxen</p> <p>Serenace Haloperidol</p> <p>Norpace New Disopyramide Phosphate</p>	<p>Specialty</p> <p>HerMab Trastuzumab</p> <p>Adlumab Adalimumab</p> <p>Ivzumab Bevacizumab</p> <p>Zestmab Rituximab</p> <p>T-JAKi Tofacitinib</p> <p>FC-IRO Ferric Carboxymaltose Injection</p> <p>Denbri Denosumab</p>	<p>Chronic</p> <p>SacuNew Sacubitril+ Valsartan</p> <p>NuGliptin Vildagliptin</p> <p>GliptiNext Teneligliptin</p> <p>DPO 5 to 10 Dapagliflozin</p> <p>Solifirst Solifenacin</p> <p>Mirasmart S Mirabegron</p>	<p>Life Cycle Management (Existing Products)</p> <p>Azoran 75 Azathioprine 75 mg Tablets</p> <p>Aldactone T Spironolactone 50 mg + Furosemide 20 mg Tablets</p> <p>Aldactone F Spironolactone 60mg + Furosemide 20mg</p> <p>Naprosyn 250 + 500 Naproxen Sodium Tablet USP 275 mg / 550 mg</p> <p>Naprosyn + Gel THE PAIN RELIEF EXPERT</p> <p>Naprosyn M Sumatriptan & Naproxen Sodium Tablets</p> <p>ROMILAST-BL Risperidone 1 mg Tablets</p> <p>Tricaine Alma 2 Almogate 500 mg and simeticone 25 mg Oral Suspension 7.5 ml</p>



IF Key Products

Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline

Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope



APIs Key Products

Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole



Key Business Highlights

All round performance in FY26 with robust financial metrics



8.3%

Revenue Growth
v/s FY25

Sustained growth momentum to record
707.5 cr. revenue in FY26



24.4%

EBITDA %

Strong profitability leading to robust EBITDA
generation of 172.7 cr. in FY26



28.5%

ROCE

Strong return ratios achieved through
disciplined capital allocation



21.1%

ROE

Improved shareholder returns driven
by higher profitability



₹69.6

EPS

Strong earnings growth supported by
operational performance



₹185+ Cr

Capex


Growth & capacity investments
over last 5 years

Consistent execution across growth, profitability and capital efficiency driving long-term value creation

Note: ROE is post-tax

Consistent Outperformance in Domestic Formulations business (69% sales contributor)

Sustained Outperformance vs IPM²



Key Business highlights

DF business grew
1.6x
than the market in FY26¹

Emerged in Q4 as the
4th
fastest growing company in IPM²







Sharp jump in IPM² rank to
52nd
from 58th rank in FY26

Naprosyn grew by
16%
in FY26; up from 4% in FY25

Among the fastest growing pharma companies in India

1. Source: Pharmarack March 2026 database 2. IPM: Indian Pharma Market

Domestic Formulations: Strategies that enabled market-beating growth

- **Focus on High Growth Therapy**
 - Deepened focus on key therapy baskets like nephro, rheuma, oncology and pain management recording market-beating growth rates in FY26
- **Strong Brands Gaining Momentum**
 - Key brands like Naprosyn grew at market-beating 15.6% growth in FY26; almost all key brands recording double digit growth
- **Successful New Product Launches**
 - Sharp and focused new launches leading to healthy contribution of 4.1% in overall growth
- **Better Field Execution & Productivity**
 - Leveraging digital tools, capability building and salesforce effectiveness; specialty business recording one of industry-highest PCPM of 17 lakhs
- **Volume-led growth**
 - While the Indian Pharma Market (IPM) grew volumes by only 0.7% in FY26; RPGLS recorded a robust 6.4% volume growth in FY26
- **Strong Business Discipline & Efficiency**
 - Continuous improvement in business hygiene parameters, expiry reduction and improved call average

Focusing on growth & efficiency initiatives to drive API and International Formulations business

Driving improvement across cost, quality, growth & productivity

1

Building manufacturing capacity



Enhancing manufacturing capabilities through focused capex and automation initiatives

2

Driving Cost Efficiency



Implementing further cost optimization initiatives to improve competitiveness

3

Accelerating R&D output



Continuous investment in R&D and CDMO to drive new launches and specialty expansion

4

Quality & Compliance



Continuous strengthening of our quality systems and compliances

5

Leveraging Digital & Productivity



Using digital initiatives to enhance execution, reach and overall productivity

6

Expanding Global Presence



Strengthening our footprint across both regulated and emerging markets



Financials



Consistent market-beating growth backed by healthy profitability and cashflows

Rs. crores

Revenue growth at 12.7%
5-year CAGR

Consistent focus on improving
margins and efficiency

Significant cash reserves¹
(from operations)



Consistent market-beating
performance across years

PBT improvement from 13.8%
in FY21 to 21.2% in FY26

Robust cashflow generation despite
185+ cr. capex in this period

1. Current cash reserve (including cashflow from exceptional items) is 276.5 cr.

Continued strengthening of our balance sheet in FY26

Improvements recorded in ICRA Rating

- Long term rating reaffirmed at **A+** and outlook retained as stable
- Short term rating reaffirmed at **A1**



Factors affecting rating affirmation

- A robust capital structure and strong debt servicing indicators based on
 - Healthy cash flows
- Steady growth in Top-line and improving operating margins
- Large brands in the Indian Pharmaceutical Industry
- Expansion of product portfolio and geographical presence augur well for growth prospects

Continued focus on delivering environmental-friendly growth

48.5% carbon emission
reduction in FY26


40% reduction in hazardous
waste management in FY26



48% improvement in
energy efficiency in FY26

18% reduction in water
consumption achieved in FY26

RPGS continues to focus on execution across our well-defined strategic framework



1. Monoclonal antibodies



hello happiness